Clinical trial · Interventional
Biweekly Gemcitabine-Oxaliplatin and Dexamethasone for Relapsed/Refractory Malignant Lymphoma
NCT00561301CI-TRIAL-00000989unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
\- To evaluate the feasibility of combination chemotherapies comprising of gemcitabine-dexamethasone-oxaliplatin for patients with refractory or relapsed malignant non-Hodgkin lymphoma (NHL)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| GemDOx | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- NO_INTERVENTION
- label
- 1
- interventionNames
- Drug: GemDOx
Primary outcomes (1)
- measure
- objective response rate
- timeFrame
- 10/2009
Secondary outcomes (1)
- measure
- toxicities, progression-free survival, overall survival, ASCC efficacy, rate for proceeding to ASCT
- timeFrame
- 10/2009
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 15 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who have refractory to first-line CHOP-like regimen * Patients who have first relapse after * first-line CHOP-like regimen * upfront autologous or allogeneic hematopoietic stem cell transplantation * Age 15 years or more * ECOG performance status ≤ 2 * Adequate bone marrow function * Adequate kidney,liver,cardiac Exclusion Criteria: * Patients who have received GEM or OX
References
Publications (0)
Data not yet available
No reference posted for this study.